TP21 GMBH

Their core work

TP21 is a Berlin-based SME that provides technology and data management services to biomedical and clinical research consortia. Their project portfolio spans clinical decision support, medical imaging informatics, neuroscience data platforms, and gene delivery technologies. They consistently serve as a technology partner in large health research projects, contributing IT infrastructure, data processing, and simulation capabilities to multi-partner European consortia working on complex medical challenges.

What they specialise in

How they've shifted over time

TP21's early H2020 work (2015-2016) centered on neurorehabilitation and neural plasticity, particularly spinal cord injury recovery and brain barrier research. From 2017 onward, they shifted toward computational approaches — brain modeling, big data, cloud computing, and decision support systems for neurodegenerative disease. Their latest project (ENDOSCAPE, 2019) marks a further pivot into biotechnology with non-viral gene delivery, suggesting a broadening beyond pure informatics into translational biotech applications.

TP21 is moving from clinical data services toward computationally intensive biomedical applications, with a new branch into gene delivery technology — signaling ambitions beyond IT support into deeper biotech involvement.

How they like to work

TP21 operates exclusively as a partner, never as coordinator — across all 7 projects they joined existing consortia rather than leading them. With 81 unique partners across 18 countries, they maintain a broad and non-exclusive network, suggesting they are sought after as a reliable technology contributor rather than building tight recurring partnerships. This makes them an accessible and experienced consortium partner for new project proposals.

Extensive network of 81 unique partners across 18 countries, built entirely through participant roles in large RIA consortia. Their reach is pan-European with no obvious geographic concentration, reflecting the broad international composition of the health research projects they join.

What sets them apart

TP21 sits at the intersection of health research and digital technology — a relatively rare combination for a Berlin SME. While many IT companies serve healthcare, TP21's direct involvement in clinical and neuroscience research consortia (not just as a software vendor but as a research participant) gives them deep domain understanding. Their dual competence in medical imaging informatics and neuroscience data platforms makes them a strong technology partner for health projects that need computational infrastructure with genuine biomedical literacy.

Highlights from their portfolio

• VirtualBrainCloud
  Their highest-funded project (EUR 376,250) combining brain modeling, big data, cloud, and HPC for personalized neurodegenerative disease management — represents the convergence of their health and digital expertise.
• ENDOSCAPE
  Their most recent project (EUR 370,000) and a strategic pivot into gene delivery biotechnology, signaling expansion beyond informatics into translational medicine.
• NISCI
  A clinical trial for spinal cord injury treatment using Nogo-A antibodies — demonstrates involvement in therapeutic development, not just data management.